Corrections to multidentate small-molecule inhibitors of Vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells (Journal of Medicinal Chemistry (2009) 52, (6716) DOI 10.1021/jm901016k);Multidentate small-molecule inhibitors of Vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells

Journal of Medicinal Chemistry

Volumn 52, Issue 21, 2009, Pages 6716-6723

  Wu, Shuangding ^a   Vossius, Sofie ^b   Rahmouni, Souad ^b   Miletic, Ana V ^a   Vang, Torkel ^a   Vazquez Rodriguez, Jesus ^a   Cerignoli, Fabio ^a   Arimura, Yutaka ^a   Williams, Scott ^a   Hayes, Tikva ^a   Moutschen, Michel ^b   Vasile, Stefan ^a   Pellecchia, Maurizio ^a   Mustelin, Tomas ^a   Tautz, Lutz ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; PHOSPHATASE; UNCLASSIFIED DRUG; VACCINIA H1 RELATED PHOSPHATASE;

ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROPHOBICITY; KERATINOCYTE; STRUCTURE ACTIVITY RELATION; UTERINE CERVIX CANCER; VACCINIA; X RAY CRYSTALLOGRAPHY;

EID: 71049126149     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901634z     Document Type: Erratum

References (31)

1. Bialy, L.; Waldmann, H. Inhibitors of protein tyrosine phosphatases: next-generation drugs? Angew. Chem., Int. Ed. 2005, 44, 3814-3839. (Pubitemid 40885689)
2. Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 2006, 7, 833-846.
3. Ostman, A.; Hellberg, C.; Bohmer, F. D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 2006, 6, 307-320.
4. Tautz, L.; Pellecchia, M.; Mustelin, T. Targeting the PTPome in human disease. Expert Opin. Ther. Targets 2006, 10, 157-177.
5. Jiang, Z. X.; Zhang, Z. Y. Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev. 2008, 27, 263-272.
6. Alonso, A.; Sasin, J.; Bottini, N.; Friedberg, I.; Friedberg, I.; Osterman, A.; Godzik, A.; Hunter, T.; Dixon, J.; Mustelin, T. Protein tyrosine phosphatases in the human genome. Cell 2004, 117, 699-711. (Pubitemid 38748887)
7. Ishibashi, T.; Bottaro, D. P.; Chan, A.; Miki, T.; Aaronson, S. A. Expression cloning of a human dual-specificity phosphatase. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 12170-12174.
8. Yuvaniyama, J.; Denu, J. M.; Dixon, J. E.; Saper, M. A. Crystal structure of the dual specificity protein phosphatase VHR. Science 1996, 272, 1328-1331. (Pubitemid 26199971)
9. Alonso, A.; Saxena, M.; Williams, S.; Mustelin, T. Inhibitory role for dual specificity phosphataseVHRin T cell antigen receptor and CD28-induced Erk and Jnk activation. J. Biol. Chem. 2001, 276, 4766-4771.
10. Todd, J. L.; Rigas, J. D.; Rafty, L. A.; Denu, J. M. Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK). Oncogene 2002, 21, 2573-2583.
11. Todd, J. L.; Tanner, K. G.; Denu, J. M. Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway. J. Biol. Chem. 1999, 274, 13271-13280.
12. Waskiewicz, A. J.; Cooper, J. A. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr. Opin. Cell Biol. 1995, 7, 798-805.
13. Robinson, M. J.; Cobb, M. H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 1997, 9, 180-186.
14. Ip, Y. T.; Davis, R. J. Signal transduction by the c-Jun N-terminal kinase (JNK) - from inflammation to development. Curr. Opin. Cell Biol. 1998, 10, 205-219.
15. Canagarajah, B. J.; Khokhlatchev, A.; Cobb, M. H.; Goldsmith, E. J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997, 90, 859-869.
16. Rahmouni, S.; Cerignoli, F.; Alonso, A.; Tsutji, T.; Henkens, R.; Zhu, C.; Louis-dit-Sully, C.; Moutschen, M.; Jiang, W.; Mustelin, T. Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat. Cell Biol. 2006, 8, 524-531.
17. Woods, D.; Parry, D.; Cherwinski, H.; Bosch, E.; Lees, E.; McMahon, M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21 Cip1. Mol. Cell. Biol. 1997, 17, 5598-5611.
18. Sewing, A.; Wiseman, B.; Lloyd, A. C.; Land, H. High-intensity Raf signal causes cell cycle arrest mediated by p21 Cip1. Mol. Cell. Biol. 1997, 17, 5588-5597.
19. Serrano, M.; Lin, A. W.; McCurrach, M. E.; Beach, D.; Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88, 593-602.
20. Pumiglia, K. M.; Decker, S. J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 448-452.
21. Wang, W.; Chen, J. X.; Liao, R.; Deng, Q.; Zhou, J. J.; Huang, S.; Sun, P. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol. Cell. Biol. 2002, 22, 3389-3403.
22. Henkens, R.; Delvenne, P.; Arafa, M.; Moutschen, M.; Zeddou, M.; Tautz, L.; Boniver, J.; Mustelin, T.; Rahmouni, S. Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC Cancer 2008, 8, 147. (Pubitemid 351803799)
23. Willett, P. Similarity-based virtual screening using 2D fingerprints. Drug Discovery Today 2006, 11, 1046-1053. (Pubitemid 44792477)
24. Schumacher, M. A.; Todd, J. L.; Rice, A. E.; Tanner, K. G.; Denu, J. M. Structural basis for the recognition of a bisphosphorylated MAP kinase peptide by human VHR protein Phosphatase. Biochemistry 2002, 41, 3009-3017.
25. Tautz, L.; Mustelin, T. Strategies for developing protein tyrosine phosphatase inhibitors. Methods 2007, 42, 250-260. (Pubitemid 46783589)
26. Barr, A. J.; Ugochukwu, E.; Lee, W. H.; King, O. N.; Filippakopoulos, P.; Alfano, I.; Savitsky, P.; Burgess-Brown, N. A.; Muller, S.; Knapp, S. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 2009, 136, 352-363.
27. Tautz, L.; Bruckner, S.; Sareth, S.; Alonso, A.; Bogetz, J.; Bottini, N.; Pellecchia, M.; Mustelin, T. Inhibition of Yersinia tyrosine phosphatase by furanyl salicylate compounds. J. Biol. Chem. 2005, 280, 9400-9408.
28. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276, 307-326. (Pubitemid 27085611)
29. Collaborative Computational Project, No.4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
30. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132.
31. Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 1355-1363.